MX2018002543A - Composiciones que comprenden compuestos de urolitina. - Google Patents

Composiciones que comprenden compuestos de urolitina.

Info

Publication number
MX2018002543A
MX2018002543A MX2018002543A MX2018002543A MX2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A
Authority
MX
Mexico
Prior art keywords
compositions
urolithin
urolithin compounds
compounds
provides
Prior art date
Application number
MX2018002543A
Other languages
English (en)
Inventor
Blanco-Bose William
Andreux Penelope
Rinsch Christopher
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of MX2018002543A publication Critical patent/MX2018002543A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona composiciones que comprenden un triglicérido de cadena media y una urolitina. La invención también proporciona usos y métodos asociados con, o hace uso de las composiciones, tales como un medicamento, suplemento dietético, alimento funcional o alimento médico y en el tratamiento y/o profilaxis de una afección patológica relacionada con los músculos.
MX2018002543A 2015-08-28 2016-08-26 Composiciones que comprenden compuestos de urolitina. MX2018002543A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1515387.7A GB201515387D0 (en) 2015-08-28 2015-08-28 Compositions
PCT/EP2016/070255 WO2017036992A1 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds

Publications (1)

Publication Number Publication Date
MX2018002543A true MX2018002543A (es) 2018-06-15

Family

ID=54326542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002543A MX2018002543A (es) 2015-08-28 2016-08-26 Composiciones que comprenden compuestos de urolitina.

Country Status (15)

Country Link
US (4) US10695320B2 (es)
EP (1) EP3340977B1 (es)
JP (3) JP7227003B2 (es)
KR (2) KR102822365B1 (es)
CN (1) CN108289879A (es)
AU (1) AU2016314987B2 (es)
BR (1) BR112018003745B1 (es)
CA (1) CA2996724C (es)
ES (1) ES2936723T3 (es)
GB (1) GB201515387D0 (es)
MX (1) MX2018002543A (es)
PT (1) PT3340977T (es)
RU (1) RU2754761C2 (es)
SG (1) SG10202001793PA (es)
WO (1) WO2017036992A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
WO2018162650A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Methods for improving mitophagy in subjects
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
US20230372291A1 (en) 2020-09-25 2023-11-23 Societe Des Produits Nestle S.A. Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
WO2022113693A1 (ja) * 2020-11-30 2022-06-02 国立研究開発法人産業技術総合研究所 筋ジストロフィー治療剤、中心静脈栄養用組成物、筋組織の炎症抑制剤および筋ジストロフィーの抗炎症用食品組成物
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
EP4284781A1 (en) 2021-01-27 2023-12-06 Vandria SA Urolithin derivatives and methods of use thereof
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
WO2023199908A1 (ja) * 2022-04-11 2023-10-19 株式会社ダイセル 乳化組成物の製造方法
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
WO2024142098A1 (en) * 2022-12-27 2024-07-04 Indian Institute Of Science A method for the treatment of epilepsy
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
EP4555997A1 (en) * 2023-11-15 2025-05-21 Science4Beauty Sp. z o.o. Water-soluble composition comprising urolithin
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
RO121117B1 (ro) 1996-03-26 2006-12-29 Eli Lilly And Company Compoziţie farmaceutică conţinând derivaţi de benzotiofen şi utilizarea acesteia
WO1999053941A1 (fr) * 1998-04-15 1999-10-28 Shionogi & Co., Ltd. Preparations orales contenant des derives de trh
ES2301477T3 (es) 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
US6623734B2 (en) * 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
JP5147239B2 (ja) 2004-09-29 2013-02-20 三栄源エフ・エフ・アイ株式会社 コエンザイムｑ１０含有乳化組成物
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP2145904A1 (de) 2008-07-18 2010-01-20 Basf Se Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen
LT2343982T (lt) 2008-09-17 2017-07-25 Chiasma Inc. Farmacinės kompozicijos ir susiję pateikimo būdai
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
SG10201704745UA (en) 2010-03-19 2017-07-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
PL2550092T3 (pl) 2010-03-22 2019-01-31 Instillo Gmbh Sposób wytwarzania mikro- lub nanocząstek
RU2012149115A (ru) 2010-04-20 2014-05-27 Сипла Лимитед Фармацевтическая композиция
EP2643317A1 (en) 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
JP2012111712A (ja) 2010-11-25 2012-06-14 Toyo Capsule Kk 油性ビタミンｃ経口投与用組成物
PT3372228T (pt) * 2010-12-23 2025-05-26 Amazentis Sa Método não-terapêutico de aumento ou manutenção da função mitocondrial
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CA2826884A1 (en) * 2012-09-14 2014-03-14 Natreon, Inc. Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit
GB201323008D0 (en) * 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions

Also Published As

Publication number Publication date
SG10202001793PA (en) 2020-04-29
JP2018533618A (ja) 2018-11-15
KR20240060826A (ko) 2024-05-08
AU2016314987B2 (en) 2021-07-08
CA2996724C (en) 2024-05-21
WO2017036992A1 (en) 2017-03-09
RU2754761C2 (ru) 2021-09-07
US20220323407A1 (en) 2022-10-13
KR102660005B1 (ko) 2024-04-22
PT3340977T (pt) 2023-01-31
HK1257500A1 (en) 2019-10-25
US10695320B2 (en) 2020-06-30
CN108289879A (zh) 2018-07-17
JP7227003B2 (ja) 2023-02-21
KR102822365B1 (ko) 2025-06-17
KR20180037052A (ko) 2018-04-10
US20180243261A1 (en) 2018-08-30
RU2018108136A (ru) 2019-09-30
BR112018003745A2 (pt) 2018-09-25
US20240148690A1 (en) 2024-05-09
ES2936723T3 (es) 2023-03-21
BR112018003745B1 (pt) 2023-11-07
AU2016314987A1 (en) 2018-03-29
JP2022177130A (ja) 2022-11-30
GB201515387D0 (en) 2015-10-14
EP3340977B1 (en) 2022-11-02
CA2996724A1 (en) 2017-03-09
RU2018108136A3 (es) 2020-01-31
EP3340977A1 (en) 2018-07-04
US20200323818A1 (en) 2020-10-15
US11337957B2 (en) 2022-05-24
US11925616B2 (en) 2024-03-12
JP2025004129A (ja) 2025-01-14

Similar Documents

Publication Publication Date Title
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
SA517381819B1 (ar) التعديل المناعي
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
MY187540A (en) Compounds active towards bromodomains
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2017009720A (es) Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas.
MX2017002489A (es) Agentes terapeuticos humanos.
PH12018500994A1 (en) Nutritional compositions containing butyrate and uses thereof
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
HK1245658A1 (zh) 可用於治療ibd患者的營養組合物
IL259183B (en) Food supplement and preparation for the treatment of metabolic syndrome
IL248271A0 (en) Nutritional compounds for lowering blood sugar levels and maintaining weight
ZA201706915B (en) Methods and compositions for the treatment of cellulosic biomass and products produced thereby
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
TR201908639T4 (tr) Dejeneratif göz bozukluklarının önlenmesi ve veya tedavisine yönelik safran bazlı bileşimler.
PH12016501838A1 (en) Compounds and their methods of use
ZA201802606B (en) Compositions for dental varnishes and methods of making and using same
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
PH12019550209A1 (en) A nutritional composition for use to enhance attention and/or reduce impulsivity
HK1258999A1 (zh) 用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物
MX2015001648A (es) Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
MY188896A (en) Methods and compositions for reducing digestive/absorptive rates and ratio of food/drinks or reducing a digestive solution